Per Lundin
Direttore/Membro del Consiglio presso COMBIGENE AB
Posizioni attive di Per Lundin
Società | Posizione | Inizio | Fine |
---|---|---|---|
COMBIGENE AB | Direttore/Membro del Consiglio | 01/01/2020 | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | 20/12/2018 | - |
Amministratore Delegato | 29/04/2024 | - | |
Fondatore | 01/01/2016 | - | |
Direttore operativo | 01/01/2016 | - | |
Corporate Officer/Principal | - | 29/04/2024 | |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Per Lundin
Precedenti posizioni note di Per Lundin
Società | Posizione | Inizio | Fine |
---|---|---|---|
IsletOne Therapeutics | Direttore/Membro del Consiglio | 01/12/2012 | 01/09/2019 |
Amministratore Delegato | 01/12/2012 | 01/04/2016 | |
Fondatore | 01/12/2012 | 01/04/2016 | |
Thomson Reuters Holdings AB | Corporate Officer/Principal | 01/11/2011 | 01/04/2016 |
Formazione di Per Lundin
Karolinska Institutet | Doctorate Degree |
Royal Institute of Technology | Graduate Degree |
Stockholm Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Svezia | 7 |
Stati Uniti | 2 |
Regno Unito | 2 |
Posizioni
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Founder | 2 |
Settori
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
COMBIGENE AB | Health Technology |
Aziende private | 4 |
---|---|
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Thomson Reuters Holdings AB | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
IsletOne Therapeutics |
- Borsa valori
- Insiders
- Per Lundin
- Esperienza